Mucosal leishmaniasis: the experience of a Brazilian referral center
Abstract INTRODUCTION Pentavalent antimonials (Sbv) are the most commonly used drugs for the treatment of mucosal leishmaniasis (ML), despite their high toxicity and only moderate efficacy. The aim of this study was to report therapeutic responses with different available options for ML. METHODS...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Medicina Tropical (SBMT)
|
| Series: | Revista da Sociedade Brasileira de Medicina Tropical |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000300318&lng=en&tlng=en |
| _version_ | 1818534224549904384 |
|---|---|
| author | Mariana Junqueira Pedras Janaína de Pina Carvalho Rosiana Estéfane da Silva Dario Brock Ramalho Maria Camilo Ribeiro de Senna Hugo Silva Assis Moreira Lorena Zaine Matos Martinho Ana Rabello Gláucia Cota |
| author_facet | Mariana Junqueira Pedras Janaína de Pina Carvalho Rosiana Estéfane da Silva Dario Brock Ramalho Maria Camilo Ribeiro de Senna Hugo Silva Assis Moreira Lorena Zaine Matos Martinho Ana Rabello Gláucia Cota |
| author_sort | Mariana Junqueira Pedras |
| collection | DOAJ |
| description | Abstract INTRODUCTION Pentavalent antimonials (Sbv) are the most commonly used drugs for the treatment of mucosal leishmaniasis (ML), despite their high toxicity and only moderate efficacy. The aim of this study was to report therapeutic responses with different available options for ML. METHODS This study was based on a review of clinical records of 35 patients (24 men and 11 women) treated between 2009 and 2015. RESULTS The median age of patients was 63 years, and the median duration of the disease was 24 months. Seventeen patients received Sbv, while nine patients were treated with liposomal amphotericin B (AmB), and another nine patients were treated with fluconazole. Patients treated with AmB received a total median accumulated dose of 2550mg. The mean duration of azole use was 120 days, and the daily dose ranged from 450 to 900mg. At the three-month follow-up visit, the cure rate was 35%, 67%, and 22% for Sbv, AmB, and azole groups, respectively. At the six-month follow-up visit, the cure rates for Sbv, AmB, and azole groups were 71%, 78%, and 33%, respectively. CONCLUSIONS There is a scarcity of effective ML treatment alternatives, and based on our observations, fluconazole is not a valid treatment option. |
| first_indexed | 2024-12-11T18:08:56Z |
| format | Article |
| id | doaj.art-869345020ee94959bba19ec9052c91b9 |
| institution | Directory Open Access Journal |
| issn | 1678-9849 |
| language | English |
| last_indexed | 2024-12-11T18:08:56Z |
| publisher | Sociedade Brasileira de Medicina Tropical (SBMT) |
| record_format | Article |
| series | Revista da Sociedade Brasileira de Medicina Tropical |
| spelling | doaj.art-869345020ee94959bba19ec9052c91b92022-12-22T00:55:38ZengSociedade Brasileira de Medicina Tropical (SBMT)Revista da Sociedade Brasileira de Medicina Tropical1678-984951331832310.1590/0037-8682-0478-2017S0037-86822018000300318Mucosal leishmaniasis: the experience of a Brazilian referral centerMariana Junqueira PedrasJanaína de Pina CarvalhoRosiana Estéfane da SilvaDario Brock RamalhoMaria Camilo Ribeiro de SennaHugo Silva Assis MoreiraLorena Zaine Matos MartinhoAna RabelloGláucia CotaAbstract INTRODUCTION Pentavalent antimonials (Sbv) are the most commonly used drugs for the treatment of mucosal leishmaniasis (ML), despite their high toxicity and only moderate efficacy. The aim of this study was to report therapeutic responses with different available options for ML. METHODS This study was based on a review of clinical records of 35 patients (24 men and 11 women) treated between 2009 and 2015. RESULTS The median age of patients was 63 years, and the median duration of the disease was 24 months. Seventeen patients received Sbv, while nine patients were treated with liposomal amphotericin B (AmB), and another nine patients were treated with fluconazole. Patients treated with AmB received a total median accumulated dose of 2550mg. The mean duration of azole use was 120 days, and the daily dose ranged from 450 to 900mg. At the three-month follow-up visit, the cure rate was 35%, 67%, and 22% for Sbv, AmB, and azole groups, respectively. At the six-month follow-up visit, the cure rates for Sbv, AmB, and azole groups were 71%, 78%, and 33%, respectively. CONCLUSIONS There is a scarcity of effective ML treatment alternatives, and based on our observations, fluconazole is not a valid treatment option.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000300318&lng=en&tlng=enMucosal leishmaniasisTherapyMeglumine antimoniateAmphotericin BAzole |
| spellingShingle | Mariana Junqueira Pedras Janaína de Pina Carvalho Rosiana Estéfane da Silva Dario Brock Ramalho Maria Camilo Ribeiro de Senna Hugo Silva Assis Moreira Lorena Zaine Matos Martinho Ana Rabello Gláucia Cota Mucosal leishmaniasis: the experience of a Brazilian referral center Revista da Sociedade Brasileira de Medicina Tropical Mucosal leishmaniasis Therapy Meglumine antimoniate Amphotericin B Azole |
| title | Mucosal leishmaniasis: the experience of a Brazilian referral center |
| title_full | Mucosal leishmaniasis: the experience of a Brazilian referral center |
| title_fullStr | Mucosal leishmaniasis: the experience of a Brazilian referral center |
| title_full_unstemmed | Mucosal leishmaniasis: the experience of a Brazilian referral center |
| title_short | Mucosal leishmaniasis: the experience of a Brazilian referral center |
| title_sort | mucosal leishmaniasis the experience of a brazilian referral center |
| topic | Mucosal leishmaniasis Therapy Meglumine antimoniate Amphotericin B Azole |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000300318&lng=en&tlng=en |
| work_keys_str_mv | AT marianajunqueirapedras mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT janainadepinacarvalho mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT rosianaestefanedasilva mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT dariobrockramalho mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT mariacamiloribeirodesenna mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT hugosilvaassismoreira mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT lorenazainematosmartinho mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT anarabello mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT glauciacota mucosalleishmaniasistheexperienceofabrazilianreferralcenter |